$14.37
1.22% yesterday
Nasdaq, Oct 15, 10:00 pm CET
ISIN
US71716E1055
Symbol
PHAR

Pharming Group N.V. - ADR Target price 2025 - Analyst rating & recommendation

Pharming Group N.V. - ADR Classifications & Recommendation:

Buy
92%
Hold
8%

Pharming Group N.V. - ADR Price Target

Target Price $2.85
Price $14.37
Deviation
Number of Estimates 8
8 Analysts have issued a price target Pharming Group N.V. - ADR 2026 . The average Pharming Group N.V. - ADR target price is $2.85. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 12 Analysts recommend Pharming Group N.V. - ADR to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Pharming Group N.V. - ADR stock has an average upside potential 2026 of . Most analysts recommend the Pharming Group N.V. - ADR stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2031

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 297.20 349.81
21.15% 17.70%
EBITDA Margin 2.51% 4.23%
157.26% 68.75%
Net Margin -3.98% 7.36%
7.36% 284.75%

8 Analysts have issued a sales forecast Pharming Group N.V. - ADR 2025 . The average Pharming Group N.V. - ADR sales estimate is

$350m
Unlock
. This is
2.93% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$378m 11.29%
Unlock
, the lowest is
$306m 10.03%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $297m 21.15%
2025
$350m 17.70%
Unlock
2026
$393m 12.25%
Unlock
2027
$453m 15.47%
Unlock
2028
$431m 5.01%
Unlock
2029
$462m 7.32%
Unlock
2030
$526m 13.80%
Unlock
2031
$485m 7.71%
Unlock

6 Analysts have issued an Pharming Group N.V. - ADR EBITDA forecast 2025. The average Pharming Group N.V. - ADR EBITDA estimate is

$14.8m
Unlock
. This is
63.27% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$27.4m 31.90%
Unlock
, the lowest is
$2.5m 93.67%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $7.5m 169.37%
2025
$14.8m 98.40%
Unlock
2026
$22.4m 51.21%
Unlock
2027
$31.5m 40.79%
Unlock
2028
$130m 314.08%
Unlock
2029
$179m 37.63%
Unlock
2030
$236m 31.41%
Unlock

EBITDA Margin

2024 2.51% 157.26%
2025
4.23% 68.75%
Unlock
2026
5.69% 34.52%
Unlock
2027
6.94% 21.97%
Unlock
2028
30.25% 335.88%
Unlock
2029
38.80% 28.26%
Unlock
2030
44.80% 15.46%
Unlock

8 Pharming Group N.V. - ADR Analysts have issued a net profit forecast 2025. The average Pharming Group N.V. - ADR net profit estimate is

$25.7m
Unlock
. This is
413.90% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$109m 1,428.66%
Unlock
, the lowest is
$-14.8m 80.12%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-11.8m 12.23%
2025
$25.7m 317.40%
Unlock
2026
$43.2m 67.91%
Unlock
2027
$46.6m 7.77%
Unlock
2028
$77.6m 66.66%
Unlock
2029
$113m 45.18%
Unlock
2030
$154m 36.50%
Unlock

Net Margin

2024 -3.98% 7.36%
2025
7.36% 284.75%
Unlock
2026
11.01% 49.59%
Unlock
2027
10.27% 6.72%
Unlock
2028
18.02% 75.46%
Unlock
2029
24.38% 35.29%
Unlock
2030
29.25% 19.98%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2031

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.02 0.04
0.00% 300.00%
P/E 382.56
EV/Sales 2.79

8 Analysts have issued a Pharming Group N.V. - ADR forecast for earnings per share. The average Pharming Group N.V. - ADR EPS is

$0.04
Unlock
. This is
500.00% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$0.16 1,700.00%
Unlock
, the lowest is
$-0.02 100.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.02 0.00%
2025
$0.04 300.00%
Unlock
2026
$0.06 50.00%
Unlock
2027
$0.07 16.67%
Unlock
2028
$0.11 57.14%
Unlock
2029
$0.16 45.45%
Unlock
2030
$0.22 37.50%
Unlock

P/E ratio

Current -1,437.46 407.34%
2025
382.56 126.61%
Unlock
2026
227.85 40.44%
Unlock
2027
211.45 7.20%
Unlock
2028
126.87 40.00%
Unlock
2029
87.39 31.12%
Unlock
2030
64.02 26.74%
Unlock

Based on analysts' sales estimates for 2025, the Pharming Group N.V. - ADR stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.87 56.83%
2025
2.79 2.74%
Unlock
2026
2.49 10.91%
Unlock
2027
2.15 13.40%
Unlock
2028
2.27 5.28%
Unlock
2029
2.11 6.82%
Unlock
2030
1.86 12.12%
Unlock
2031
2.01 8.36%
Unlock

P/S ratio

Current 2.87 44.05%
2025
2.78 2.85%
Unlock
2026
2.48 10.91%
Unlock
2027
2.15 13.40%
Unlock
2028
2.26 5.27%
Unlock
2029
2.11 6.82%
Unlock
2030
1.85 12.12%
Unlock
2031
2.01 8.36%
Unlock

Current Pharming Group N.V. - ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
FIRST BERLIN EQUITY RESEARCH
Locked
Locked
Locked Sep 03 2025
JEFFERIES
Locked
Locked
Locked Aug 29 2025
OPPENHEIMER & CO., INC.
Locked
Locked
Locked Aug 21 2025
PORTZAMPARC BNP PARIBAS
Locked
Locked
Locked Aug 05 2025
OPPENHEIMER & CO., INC.
Locked
Locked
Locked Jun 30 2025
OPPENHEIMER & CO., INC.
Locked
Locked
Locked Jun 29 2025
JEFFERIES
Locked
Locked
Locked May 08 2025
Analyst Rating Date
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
Locked
Sep 03 2025
Locked
JEFFERIES:
Locked
Locked
Aug 29 2025
Locked
OPPENHEIMER & CO., INC.:
Locked
Locked
Aug 21 2025
Locked
PORTZAMPARC BNP PARIBAS:
Locked
Locked
Aug 05 2025
Locked
OPPENHEIMER & CO., INC.:
Locked
Locked
Jun 30 2025
Locked
OPPENHEIMER & CO., INC.:
Locked
Locked
Jun 29 2025
Locked
JEFFERIES:
Locked
Locked
May 08 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today